Mechanisms of Neutrophil Activation: History
View Latest Version
Please note this is an old version of this entry, which may differ significantly from the current revision.
Contributor:
José Perdomo
,
Halina H. L. Leung

Neutrophil extracellular traps (NETs) are major contributors to inflammation and autoimmunity, playing a key role in the development of thrombotic disorders. NETs, composed of DNA, histones, and numerous other proteins serve as scaffolds for thrombus formation and promote platelet activation, coagulation, and endothelial dysfunction.

  • immune complex
  • neutrophil extracellular traps
  • Fc receptors
  • thrombosis

1. Introduction

Morphological changes in neutrophils, distinct from apoptosis or necrosis, upon treatment with phorbol 12-myristate 13-acetate (PMA) were described by Takei et al. in 1996 [1]. This process was later termed neutrophil extracellular traps (NETs) formation and was initially reported as a host defence mechanism against infection [2]. NETs formation has evolved into a mechanism with wide implications in biological processes and in the pathology of diabetes, cancer, autoimmunity, atherosclerosis, infections, and thrombosis. Two distinct types of NETosis have been described: a slow form of cell death that may take hours and is known as lytic or suicidal NETosis and vital NETosis, a fast process whereby neutrophils release nuclear material but remain viable and functional [3]. In fact, enucleated neutrophils are known to retain chemotactic and phagocytic functions [4].
Lytic NETosis depends on NADPH and reactive oxygen species (ROS) activity which triggers histone citrullination via peptidyl arginine deiminase (PAD4), while vital NETosis does not involve NADPH and relies on increases in intracellular calcium [5]. A sub-category of lytic NETosis, termed noncanonical NETosis, has been proposed more recently [6]. This form of NETosis is elicited in the presence of cytosolic Gram-negative bacteria and involves noncanonical inflammasomes and caspase 4/5 activation. Histone citrullination mediated by PAD4 is also present in noncanonical NETosis [7]. Both lytic and vital NETosis, however, involve nuclear the decondensation and subsequent release of chromatin into the extracellular space. Chromatin serves as the backbone for numerous NET components including histones, myeloperoxidase, elastase, and cathepsin-G [8]. Therefore, the consequences of NETs formation—antibacterial activity, inflammation, vascular occlusion—can be attributed to the activity of the diverse components of these DNA structures.
Since the description of NETs induction by PMA and bacteria [1][2], numerous stimuli of NETs formation such as viruses [9], cholesterol crystals [10], activated platelets [11][12], cytokines [13], autoantibodies [14], and immune complexes (ICs) [15][16][17] have been described. Unsurprisingly, an attendant number of neutrophil receptors have been associated with various stimuli. Activated platelets induce NETosis via the PSGL1 receptor [15][18] or via high-mobility group protein B1-RAGE interaction [19], bacteria and viruses through pattern recognition receptors and Fc receptors [20][21] and ICs via Fc receptors [15][16][22] (Figure 1).
Figure 1. Mechanisms of neutrophil activation. Summarised receptor signalling pathways implicated in NETosis. IC, immune complex; Act. platelet, activated platelets; HMB1, high-mobility group box 1; TAK1, transforming growth factor-β-activated kinase 1; RAGE, receptor for advanced glycation end-products; PSGL-1, P-selectin glycoprotein ligand-1; dotted arrows indicate intermediate signalling molecules not included in the Figure.

2. Immune Complexes and Fc Receptors

The adaptive immune response results in the production of antibodies against antigens, leading to the formation of antigen–antibody complexes. The generation of antibodies that bind to different epitopes on the antigen leads to the formation of ICs. The role of ICs in conditions such a serum sickness, vasculitis, and rheumatic disease has been documented for decades [23]. ICs have a higher affinity for Fc receptors and are normally cleared by the liver (by sinusoidal endothelial cells and Kupffer cells) and spleen via interaction with Fc receptors expressed on monocytes/macrophages and neutrophils. Neutrophils express both low- (FcγRIIA, FcγRIIB, and FcγRIIIB) and high- affinity (FcRn and FcγRI, which is expressed on activated neutrophils) IgG Fc receptors. FcαRI, a receptor for IgA, is also present on human neutrophils [24]. High-affinity receptors such as FcγRI bind IgG monomers, while the low affinity receptors have an avidity for IgG ICs or opsonised cells. IgG subclasses display distinct Fc receptor binding affinities. IgG1 and IgG3 interact with FcγRI, FcγRIIA/B, FcγRIIIB, and FcRn, while IgG2 fails to recognise FcγRI, FcγRIIB, and FcγRIIIB [25]. Some IgG2 and IgG4 ICs also recognise complement receptors on neutrophils [26].
The recognition of ICs by Fc receptors leads to cellular signalling. For example, the clustering of FcγRIIA via interaction with ICs induces a phosphorylation of the immunoreceptor tyrosine-based activation motif (ITAM) by Src kinases [27], leading to Syk signalling involving PI3K and PLCγ. This triggers diverse responses including phagocytosis and receptor internalisation, cytokine production, and oxidative burst. Murine neutrophils expressing human FcγRIIA and FcγRIIIB are able to uptake ICs, but only FcγRIIA and not FcγRIIIB transgenic mice formed NETs in response to ICs in vivo [28]. In human neutrophils, however, FcγRIIIB has been found to be involved in NETs formation [29].
Circulating ICs resulting from excessive antibody production or clearance failure can be deposited on tissues, causing inflammation, and as such are involved in the pathology of multiple conditions including autoimmune diseases such as arthritis and lupus erythematosus. Drug-mediated reactions such as heparin-induced thrombocytopenia (HIT) and vaccine-induced thrombotic thrombocytopenia (VITT) and infections including influenza and SARS-CoV-2 are facilitated by circulating ICs. In fact, the induction of platelet activation via IC activity has been known since the 1950s [30].
It should be noted that ICs also induce processes analogous to NETosis in monocytes [31]. Monocyte extracellular traps (ETs) possess a procoagulant activity, suggesting a role for these monocyte-derived structures in thrombosis (reviewed by Han et al. [32]). The more generalised nature of ET formation and its association with thrombosis is exemplified by observations of ETs of macrophage, mast cell, and eosinophil origin in coronary thrombi [33].
IgG, and more specifically IgG1, is the most common type of immunoglobulin in human serum [25]. IgG ICs have been more widely described, and it is reasonable to assume that IgG ICs are also the most abundant. Lupus erythematosus is an extensively studied autoimmune disease characterised by the presence of autoantibodies against numerous endogenous antigens including dsDNA, ribonucleoprotein, phospholipids, histones, and β2-glycoprotein I. Most of these autoantibodies are of the IgG class [34]. DNA-containing Ics found in lupus patients signal through FcγRIIA and induce ROS production in neutrophils [35]. This is reminiscent of ROS-dependent neutrophil activation, NETosis, and thrombosis induced by FcγRIIA-activating HIT Ics [36].
ADAMTS-13 ICs in thrombotic thrombocytopenic purpura are correlated with relapse [37] and markers of NETosis such as histone/DNA complexes, cell-free DNA, and citrullinated histones are present in plasma from these patients [38], suggesting a contribution of ICs in the inductions of NETosis and thrombosis in this condition. IgG ICs are also present in granulomatosis (antineutrophil cytoplasmic antibodies [39]), SARS-CoV-2 infection [40], rheumatoid arthritis [41], HIT, and VITT [15][16] (Table 1).
Thrombosis is also driven by IgA ICs (Table 1). Antibody specificity and signalling is dependent on the isotype, where IgG binds to FcγR while IgA binds to FcαR. In the context of IgG signalling, unlike low-affinity FcγRs, only high-affinity FcγRs (i.e., FcγR1) can bind monomeric IgG. All FcγRs can, however, bind to IgG aggregates or immune complexes containing IgG [42]. Similarly, monomeric IgA binds poorly to FcαR1, while large IgA complexes bind with a high avidity, leading to phagocytosis, antigen presentation [43], cytokine release [44], reactive oxygen species production [45], and NETosis [46][47][48].
The proinflammatory IgA immune complex-mediated FcαR signalling is a key pathogenic feature in IgA vasculitis (or Henoch–Schönlein purpura), an inflammatory condition where the immune system attacks the lining of blood vessels. Recently, Mayer-Hain et al. showed the requirement of neutrophil prestimulation by polymeric IgA or IgA ICs to lower the threshold for neutrophil activation. This step is critical for neutrophils to become activated and undergo NETosis upon binding to activated endothelial cells, resulting in vessel wall damage [46]. Interestingly, neutrophils isolated from IgA vasculitis patients spontaneously underwent NETosis, and NETs were proximal to endothelial cells and IgA-coated neutrophils in tissue sections of these patients [46]. A significant reduction in vessel damage in a mouse model of vasculitis was observed following NET inhibition, suggesting that NETosis is key a mediator of vasculitis pathogenesis. Although uncommon, cases of coagulation abnormalities and thrombosis have been documented in IgA vasculitis [49]. Altogether, IgA ICs prestimulate neutrophils and NETosis is a key mediator of vessel wall damage in IgA vasculitis.
The presence of IgA autoantibodies is also associated with increased disease severity, enhanced cartilage damage, and worse disease prognosis in rheumatoid arthritis [50][51][52]. The activation of neutrophils by IgA ICs, present in rheumatoid arthritis patients’ plasma and synovial fluid, leads them to undergo NETosis and secrete chemoattractants that amplify neutrophil recruitment [47] and promotes cartilage damage via neutrophil elastase [48]. IgA IC-induced NETosis can be blocked by anti-FcαR1 monoclonal antibody [47], suggesting FcαR1 inhibitors could potentially reduce cartilage damage and disability in rheumatoid arthritis patients. In antiphospholipid syndrome (APS), β2-glycoprotein I/IgA IC is strongly linked to thrombosis following transplantation [53]. NETosis is likely to be of pathological significance since NETs are known to contribute to thrombosis in APS [54].
NETosis has been well documented in bacterial (e.g., Staphylococcus aureus [55]) and viral (e.g., influenza A, HIV, SARS-CoV-2 [21]) infections. NETs exert both antimicrobial [56] and antiviral [21] activity. IgA-bacteria ICs activate FcαRI and enhance the phagocytosis of IgA-opsonized bacteria [57]. Interestingly, the phagocytosis of S. aureus is more efficient in the presence of IgA [58]. Both bacterial and viral IgA IC-induced NETosis are dependent on FcαRI and NADPH oxidase [21][58]. A lower virus titre is required to trigger NETosis in the presence of IgA compared to virus alone, and NETosis is independent of phagocytosis. Unlike NETosis induced by virus alone, IgA-virus ICs-induced NETosis does not require toll-like receptor signalling [21]. Although NETosis plays a protective role in infection, the release of reactive oxygen species, proteolytic enzymes and inflammatory mediators can enhance neutrophil infiltration and elicit tissue damage. This can result in the enhancement of disease pathogenesis in conditions such as respiratory syncytial virus [59], rhinovirus [60], influenza [61], and COVID-19 [62][63][64].
Table 1. Fc receptors implicated in IgG- and IgA-immune complex-mediated NETosis.
Condition Fc Receptor Involved Receptor Binding Specificity Antigen-Antibody Complex Reference
Influenza A FcαR1 (CD89) IgA Influenza—IgA Stacey et al. [21]
Human immunodeficiency virus (HIV) FcαR1 (CD89) IgA HIV—IgA Stacey et al. [21]
SARS-CoV-2 FcαR1 (CD89)
FcγRIIA (CD32a)		 IgA
IgG		 SARS-CoV2—IgA
Spike protein—IgG		 Stacey et al. [21]
Bye et al. [65]
Staphylococcus aureus FcαR1 (CD89) IgA S. aureus—IgA Aleyd et al. [58]
Vasculitis FcαR1 (CD89) IgA Aggregated vasculitis—IgA Mayer-Hain et al. [46]
Rheumatoid arthritis FcαR1 (CD89), FcγRI (CD64), FcγRIIA (CD32a) IgA, IgG Rheumatoid factor—IgA/IgG, citrullinated protein—anticitrullinated protein antibody (ACPA) IgG, cyclic citrullinated peptide—IgA/IgG, antineutrophil cytoplasmic antibodies (ANCA)—IgA/IgG Mathsson et al. [41]; Aleyd et al. [47];
Kempers et al. [66]
Granulomatosis with polyangiitis (Wegener’s granulomatosis) FcαR1 (CD89), FcγRIIIB (CD16b) IgA, IgG Antineutrophil cytoplasmic antibodies (ANCA)—IgA/IgG Kelley et al. [39]
Heparin-induced thrombocytopenia (HIT) FcγRIIA (CD32a) IgG Heparin—PF4 -HIT IgG Kelton et al. [67]; Chong et al. [68]
Vaccine-induced thrombotic thrombocytopenia (VITT) FcγRIIA (CD32a) IgG PF4—VITT IgG Greinacher et al. [69]
Autoimmune inflammatory disorder FcγRIIA (CD32a), FcγRIIIB (CD16b) IgG Bovine serum albumin (BSA)—IgG, human serum albumin (HAS)—IgG, cross linking—FcγRIIIB Aleman et al. [29]; Behnen et al. [22]
Systemic lupus erythematosus (SLE) FcγRIIA (CD32a) IgG DNA—IgG Bonegio et al. [35]; Bruneau et al. [70]; Patiño-Trives et al. [71]; Dema and Charles [34].

This entry is adapted from the peer-reviewed paper 10.3390/biology12101332

References

  1. Takei, H.; Araki, A.; Watanabe, H.; Ichinose, A.; Sendo, F. Rapid killing of human neutrophils by the potent activator phorbol 12-myristate 13-acetate (PMA) accompanied by changes different from typical apoptosis or necrosis. J. Leukoc. Biol. 1996, 59, 229–240.
  2. Brinkmann, V.; Reichard, U.; Goosmann, C.; Fauler, B.; Uhlemann, Y.; Weiss, D.S.; Weinrauch, Y.; Zychlinsky, A. Neutrophil extracellular traps kill bacteria. Science 2004, 303, 1532–1535.
  3. Pilsczek, F.H.; Salina, D.; Poon, K.K.H.; Fahey, C.; Yipp, B.G.; Sibley, C.D.; Robbins, S.M.; Green, F.H.Y.; Surette, M.G.; Sugai, M.; et al. A Novel Mechanism of Rapid Nuclear Neutrophil Extracellular Trap Formation in Response to Staphylococcus aureus. J. Immunol. 2010, 185, 7413–7425.
  4. Malawista, S.E.; Van Blaricom, G.; Breitenstein, M.G. Cryopreservable neutrophil surrogates. Stored cytoplasts from human polymorphonuclear leukocytes retain chemotactic, phagocytic, and microbicidal function. J. Clin. Investig. 1989, 83, 728–732.
  5. Yipp, B.G.; Kubes, P. NETosis: How vital is it? Blood 2013, 122, 2784–2794.
  6. Burgener, S.S.; Schroder, K. Neutrophil Extracellular Traps in Host Defense. Cold Spring Harb. Perspect. Biol. 2020, 12, a037028.
  7. Chen, K.W.; Monteleone, M.; Boucher, D.; Sollberger, G.; Ramnath, D.; Condon, N.D.; von Pein, J.B.; Broz, P.; Sweet, M.J.; Schroder, K. Noncanonical inflammasome signaling elicits gasdermin D-dependent neutrophil extracellular traps. Sci. Immunol. 2018, 3, eaar6676.
  8. Csomós, K.; Kristóf, E.; Jakob, B.; Csomós, I.; Kovács, G.; Rotem, O.; Hodrea, J.; Bagoly, Z.; Muszbek, L.; Balajthy, Z.; et al. Protein cross-linking by chlorinated polyamines and transglutamylation stabilizes neutrophil extracellular traps. Cell Death Dis. 2016, 7, e2332.
  9. Zhu, Y.; Chen, X.; Liu, X. NETosis and Neutrophil Extracellular Traps in COVID-19: Immunothrombosis and Beyond. Front. Immunol. 2022, 13, 838011.
  10. Warnatsch, A.; Ioannou, M.; Wang, Q.; Papayannopoulos, V. Neutrophil extracellular traps license macrophages for cytokine production in atherosclerosis. Science 2015, 349, 316–320.
  11. Jung, C.J.; Yeh, C.Y.; Hsu, R.B.; Lee, C.M.; Shun, C.T.; Chia, J.S. Endocarditis pathogen promotes vegetation formation by inducing intravascular neutrophil extracellular traps through activated platelets. Circulation 2015, 131, 571–581.
  12. Carestia, A.; Kaufman, T.; Rivadeneyra, L.; Landoni, V.I.; Pozner, R.G.; Negrotto, S.; D’Atri, L.P.; Gómez, R.M.; Schattner, M. Mediators and molecular pathways involved in the regulation of neutrophil extracellular trap formation mediated by activated platelets. J. Leukoc. Biol. 2016, 99, 153–162.
  13. Yalcinkaya, M.; Fotakis, P.; Liu, W.; Endo-Umeda, K.; Dou, H.; Abramowicz, S.; Xiao, T.; Libby, P.; Wang, N.; Tall, A.R.; et al. Cholesterol accumulation in macrophages drives NETosis in atherosclerotic plaques via IL-1β secretion. Cardiovasc. Res. 2023, 119, 969–981.
  14. Garcia-Romo, G.S.; Caielli, S.; Vega, B.; Connolly, J.; Allantaz, F.; Xu, Z.; Punaro, M.; Baisch, J.; Guiducci, C.; Coffman, R.L.; et al. Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci. Transl. Med. 2011, 3, 73ra20.
  15. Perdomo, J.; Leung, H.H.L.; Ahmadi, Z.; Yan, F.; Chong, J.J.H.; Passam, F.H.; Chong, B.H. Neutrophil activation and NETosis are the major drivers of thrombosis in heparin-induced thrombocytopenia. Nat. Commun. 2019, 10, 1322.
  16. Leung, H.H.L.; Perdomo, J.; Ahmadi, Z.; Zheng, S.S.; Rashid, F.N.; Enjeti, A.; Ting, S.B.; Chong, J.J.H.; Chong, B.H. NETosis and thrombosis in vaccine-induced immune thrombotic thrombocytopenia. Nat. Commun. 2022, 13, 5206.
  17. Holm, S.; Kared, H.; Michelsen, A.E.; Kong, X.Y.; Dahl, T.B.; Schultz, N.H.; Nyman, T.A.; Fladeby, C.; Seljeflot, I.; Ueland, T.; et al. Immune complexes, innate immunity, and NETosis in ChAdOx1 vaccine-induced thrombocytopenia. Eur. Heart J. 2021, 42, 4064–4072.
  18. Etulain, J.; Martinod, K.; Wong, S.L.; Cifuni, S.M.; Schattner, M.; Wagner, D.D. P-selectin promotes neutrophil extracellular trap formation in mice. Blood 2015, 126, 242–246.
  19. Maugeri, N.; Campana, L.; Gavina, M.; Covino, C.; De Metrio, M.; Panciroli, C.; Maiuri, L.; Maseri, A.; D’Angelo, A.; Bianchi, M.E.; et al. Activated platelets present high mobility group box 1 to neutrophils, inducing autophagy and promoting the extrusion of neutrophil extracellular traps. J. Thromb. Haemost. 2014, 12, 2074–2088.
  20. Chen, T.; Li, Y.; Sun, R.; Hu, H.; Liu, Y.; Herrmann, M.; Zhao, Y.; Muñoz, L.E. Receptor-Mediated NETosis on Neutrophils. Front. Immunol. 2021, 12, 775267.
  21. Stacey, H.D.; Golubeva, D.; Posca, A.; Ang, J.C.; Novakowski, K.E.; Zahoor, M.A.; Kaushic, C.; Cairns, E.; Bowdish, D.M.E.; Mullarkey, C.E.; et al. IgA potentiates NETosis in response to viral infection. Proc. Natl. Acad. Sci. USA 2021, 118, e2101497118.
  22. Behnen, M.; Leschczyk, C.; Möller, S.; Batel, T.; Klinger, M.; Solbach, W.; Laskay, T. Immobilized immune complexes induce neutrophil extracellular trap release by human neutrophil granulocytes via FcγRIIIB and Mac-1. J. Immunol. 2014, 193, 1954–1965.
  23. Cochrane, C.G.; Koffler, D. Immune complex disease in experimental animals and man. Adv. Immunol. 1973, 16, 185–264.
  24. Otten, M.A.; van Egmond, M. The Fc receptor for IgA (FcalphaRI, CD89). Immunol. Lett. 2004, 92, 23–31.
  25. Vidarsson, G.; Dekkers, G.; Rispens, T. IgG subclasses and allotypes: From structure to effector functions. Front. Immunol. 2014, 5, 520.
  26. Voice, J.K.; Lachmann, P.J. Neutrophil Fc gamma and complement receptors involved in binding soluble IgG immune complexes and in specific granule release induced by soluble IgG immune complexes. Eur. J. Immunol. 1997, 27, 2514–2523.
  27. Mkaddem, S.B.; Murua, A.; Flament, H.; Titeca-Beauport, D.; Bounaix, C.; Danelli, L.; Launay, P.; Benhamou, M.; Blank, U.; Daugas, E.; et al. Lyn and Fyn function as molecular switches that control immunoreceptors to direct homeostasis or inflammation. Nat. Commun. 2017, 8, 246.
  28. Chen, K.; Nishi, H.; Travers, R.; Tsuboi, N.; Martinod, K.; Wagner, D.D.; Stan, R.; Croce, K.; Mayadas, T.N. Endocytosis of soluble immune complexes leads to their clearance by FcγRIIIB but induces neutrophil extracellular traps via FcγRIIA in vivo. Blood 2012, 120, 4421–4431.
  29. Alemán, O.R.; Mora, N.; Cortes-Vieyra, R.; Uribe-Querol, E.; Rosales, C. Transforming Growth Factor-β-Activated Kinase 1 Is Required for Human FcγRIIIb-Induced Neutrophil Extracellular Trap Formation. Front. Immunol. 2016, 7, 277.
  30. Humphrey, J.H.; Jaques, R. The release of histamine and 5-hydroxytryptamine (serotonin) from platelets by antigen-antibody reactions (in vitro). J. Physiol. 1955, 128, 9–27.
  31. Granger, V.; Faille, D.; Marani, V.; Noël, B.; Gallais, Y.; Szely, N.; Flament, H.; Pallardy, M.; Chollet-Martin, S.; de Chaisemartin, L. Human blood monocytes are able to form extracellular traps. J. Leukoc. Biol. 2017, 102, 775–781.
  32. Han, Z.; Liu, Q.; Li, H.; Zhang, M.; You, L.; Lin, Y.; Wang, K.; Gou, Q.; Wang, Z.; Zhou, S.; et al. The role of monocytes in thrombotic diseases: A review. Front. Cardiovasc. Med. 2023, 10, 1113827.
  33. Pertiwi, K.R.; de Boer, O.J.; Mackaaij, C.; Pabittei, D.R.; de Winter, R.J.; Li, X.; van der Wal, A.C. Extracellular traps derived from macrophages, mast cells, eosinophils and neutrophils are generated in a time-dependent manner during atherothrombosis. J. Pathol. 2019, 247, 505–512.
  34. Dema, B.; Charles, N. Autoantibodies in SLE: Specificities, Isotypes and Receptors. Antibodies 2016, 5, 2.
  35. Bonegio, R.G.; Lin, J.D.; Beaudette-Zlatanova, B.; York, M.R.; Menn-Josephy, H.; Yasuda, K. Lupus-Associated Immune Complexes Activate Human Neutrophils in an FcγRIIA-Dependent but TLR-Independent Response. J. Immunol. 2019, 202, 675–683.
  36. Leung, H.H.L.; Perdomo, J.; Ahmadi, Z.; Yan, F.; McKenzie, S.E.; Chong, B.H. Inhibition of NADPH oxidase blocks NETosis and reduces thrombosis in heparin-induced thrombocytopenia. Blood Adv. 2021, 5, 5439–5451.
  37. Mancini, I.; Ferrari, B.; Valsecchi, C.; Pontiggia, S.; Fornili, M.; Biganzoli, E.; Peyvandi, F. ADAMTS13-specific circulating immune complexes as potential predictors of relapse in patients with acquired thrombotic thrombocytopenic purpura. Eur. J. Intern. Med. 2017, 39, 79–83.
  38. Sui, J.; Lu, R.; Halkidis, K.; Kocher, N.K.; Cao, W.; Marques, M.B.; Zheng, X.L. Plasma levels of S100A8/A9, histone/DNA complexes, and cell-free DNA predict adverse outcomes of immune thrombotic thrombocytopenic purpura. J. Thromb. Haemost. 2021, 19, 370–379.
  39. Kelley, J.M.; Monach, P.A.; Ji, C.; Zhou, Y.; Wu, J.; Tanaka, S.; Mahr, A.D.; Johnson, S.; McAlear, C.; Cuthbertson, D.; et al. IgA and IgG antineutrophil cytoplasmic antibody engagement of Fc receptor genetic variants influences granulomatosis with polyangiitis. Proc. Natl. Acad. Sci. USA 2011, 108, 20736–20741.
  40. Mazzitelli, I.; Bleichmar, L.; Ludueña, M.G.; Pisarevsky, A.; Labato, M.; Chiaradia, V.; Finocchieto, P.; Paulin, F.; Hormanstorfer, M.; Baretto, M.C.; et al. Immunoglobulin G Immune Complexes May Contribute to Neutrophil Activation in the Course of Severe Coronavirus Disease 2019. J. Infect. Dis. 2021, 224, 575–585.
  41. Mathsson, L.; Lampa, J.; Mullazehi, M.; Rönnelid, J. Immune complexes from rheumatoid arthritis synovial fluid induce FcγRIIa dependent and rheumatoid factor correlated production of tumour necrosis factor-α by peripheral blood mononuclear cells. Arthritis Res. Ther. 2006, 8, R64.
  42. Bruhns, P.; Iannascoli, B.; England, P.; Mancardi, D.A.; Fernandez, N.; Jorieux, S.; Daeron, M. Specificity and affinity of human Fc gamma receptors and their polymorphic variants for human IgG subclasses. Blood 2009, 113, 3716–3725.
  43. Chen, Y.W.; Lang, M.L.; Wade, W.F. Protein kinase C-alpha and -delta are required for FcalphaR (CD89) trafficking to MHC class II compartments and FcalphaR-mediated antigen presentation. Traffic 2004, 5, 577–594.
  44. Wu, J.M.; Ji, C.Y.; Xie, F.L.; Langefeld, C.D.; Qian, K.; Gibson, A.W.; Edberg, J.C.; Kimberly, R.P. Fc alpha RI (CD89) Alleles determine the proinflammatory potential of serum IgA. J. Immunol. 2007, 178, 3973–3982.
  45. Lang, M.L.; Kerr, M.A. Characterization of Fc alpha R-triggered Ca2+ signals: Role in neutrophil NADPH oxidase activation. Biochem. Biophys. Res. Commun. 2000, 276, 749–755.
  46. Mayer-Hain, S.; Gebhardt, K.; Neufeld, M.; Ehrchen, J.M.; Molyneux, K.; Barratt, J.; Nattkemper, E.; Gerloff, D.; Roth, J.; Vogl, T.; et al. Systemic Activation of Neutrophils by Immune Complexes Is Critical to IgA Vasculitis. J. Immunol. 2022, 209, 1048–1058.
  47. Aleyd, E.; Al, M.; Tuk, C.W.; van der Laken, C.J.; van Egmond, M. IgA Complexes in Plasma and Synovial Fluid of Patients with Rheumatoid Arthritis Induce Neutrophil Extracellular Traps via FcαRI. J. Immunol. 2016, 197, 4552–4559.
  48. Carmona-Rivera, C.; Carlucci, P.M.; Goel, R.R.; James, E.; Brooks, S.R.; Rims, C.; Hoffmann, V.; Fox, D.A.; Buckner, J.H.; Kaplan, M.J. Neutrophil extracellular traps mediate articular cartilage damage and enhance cartilage component immunogenicity in rheumatoid arthritis. JCI Insight 2020, 5, 139388.
  49. Mosalem, O.; Garcilazo, N.H.; Saleh, Y.; Abu Rous, F. Pulmonary embolism as the primary presentation of IgA vasculitis. BMJ Case Rep. 2020, 13, e235884.
  50. He, Y.T.; Zha, Q.L.; Liu, D.Y.; Lu, A.P. Relations between serum IgA level and cartilage erosion in 436 cases of rheumatoid arthritis. Immunol. Investig. 2007, 36, 285–291.
  51. Teitsson, I.; Withrington, R.H.; Seifert, M.H.; Valdimarsson, H. Prospective-Study of Early Rheumatoid-Arthritis.1. Prognostic Value of Iga Rheumatoid-Factor. Ann. Rheum. Dis. 1984, 43, 673–678.
  52. Karimifar, M.; Moussavi, H.; Babaei, M.; Akbari, M. The association of immunoglobulin A, immunoglobulin G and anti-cyclic citrullinated peptide antibodies with disease activity in seronegative rheumatoid arthritis patients. J. Res. Med. Sci. 2014, 19, 823–826.
  53. Serrano, M.; Martínez-Flores, J.A.; Pérez, D.; García, F.; Cabrera-Marante, O.; Pleguezuelo, D.; Paz-Artal, E.; Morales, J.M.; González, E.; Serrano, A. β(2)-Glycoprotein I/IgA Immune Complexes: A Marker to Predict Thrombosis after Renal Transplantation in Patients with Antiphospholipid Antibodies. Circulation 2017, 135, 1922–1934.
  54. Yalavarthi, S.; Gould, T.J.; Rao, A.N.; Mazza, L.F.; Morris, A.E.; Núñez-Álvarez, C.; Hernández-Ramírez, D.; Bockenstedt, P.L.; Liaw, P.C.; Cabral, A.R.; et al. Release of neutrophil extracellular traps by neutrophils stimulated with antiphospholipid antibodies: A newly identified mechanism of thrombosis in the antiphospholipid syndrome. Arthritis Rheumatol. 2015, 67, 2990–3003.
  55. Fuchs, T.A.; Abed, U.; Goosmann, C.; Hurwitz, R.; Schulze, I.; Wahn, V.; Weinrauch, Y.; Brinkmann, V.; Zychlinsky, A. Novel cell death program leads to neutrophil extracellular traps. J. Cell Biol. 2007, 176, 231–241.
  56. Remijsen, Q.; Kuijpers, T.W.; Wirawan, E.; Lippens, S.; Vandenabeele, P.; Vanden Berghe, T. Dying for a cause: NETosis, mechanisms behind an antimicrobial cell death modality. Cell Death Differ. 2011, 18, 581–588.
  57. Bakema, J.E.; van Egmond, M. The human immunoglobulin A Fc receptor FcalphaRI: A multifaceted regulator of mucosal immunity. Mucosal Immunol. 2011, 4, 612–624.
  58. Aleyd, E.; van Hout, M.W.; Ganzevles, S.H.; Hoeben, K.A.; Everts, V.; Bakema, J.E.; van Egmond, M. IgA enhances NETosis and release of neutrophil extracellular traps by polymorphonuclear cells via Fcα receptor I. J. Immunol. 2014, 192, 2374–2383.
  59. Cortjens, B.; de Boer, O.J.; de Jong, R.; Antonis, A.F.; Sabogal Pineros, Y.S.; Lutter, R.; van Woensel, J.B.; Bem, R.A. Neutrophil extracellular traps cause airway obstruction during respiratory syncytial virus disease. J. Pathol. 2016, 238, 401–411.
  60. Toussaint, M.; Jackson, D.J.; Swieboda, D.; Guedan, A.; Tsourouktsoglou, T.D.; Ching, Y.M.; Radermecker, C.; Makrinioti, H.; Aniscenko, J.; Bartlett, N.W.; et al. Host DNA released by NETosis promotes rhinovirus-induced type-2 allergic asthma exacerbation. Nat. Med. 2017, 23, 681–691.
  61. Narasaraju, T.; Yang, E.; Samy, R.P.; Ng, H.H.; Poh, W.P.; Liew, A.A.; Phoon, M.C.; van Rooijen, N.; Chow, V.T. Excessive neutrophils and neutrophil extracellular traps contribute to acute lung injury of influenza pneumonitis. Am. J. Pathol. 2011, 179, 199–210.
  62. Barnes, B.J.; Adrover, J.M.; Baxter-Stoltzfus, A.; Borczuk, A.; Cools-Lartigue, J.; Crawford, J.M.; Dassler-Plenker, J.; Guerci, P.; Huynh, C.; Knight, J.S.; et al. Targeting potential drivers of COVID-19: Neutrophil extracellular traps. J. Exp. Med. 2020, 217, e20200652.
  63. Middleton, E.A.; He, X.Y.; Denorme, F.; Campbell, R.A.; Ng, D.; Salvatore, S.P.; Mostyka, M.; Baxter-Stoltzfus, A.; Borczuk, A.C.; Loda, M.; et al. Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome. Blood 2020, 136, 1169–1179.
  64. Radermecker, C.; Detrembleur, N.; Guiot, J.; Cavalier, E.; Henket, M.; d’Emal, C.; Vanwinge, C.; Cataldo, D.; Oury, C.; Delvenne, P.; et al. Neutrophil extracellular traps infiltrate the lung airway, interstitial, and vascular compartments in severe COVID-19. J. Exp. Med. 2020, 217, e20201012.
  65. Bye, A.P.; Hoepel, W.; Mitchell, J.L.; Jégouic, S.; Loureiro, S.; Sage, T.; Vidarsson, G.; Nouta, J.; Wuhrer, M.; de Taeye, S.; et al. Aberrant glycosylation of anti-SARS-CoV-2 spike IgG is a prothrombotic stimulus for platelets. Blood 2021, 138, 1481–1489.
  66. Kempers, A.C.; Nejadnik, M.R.; Rombouts, Y.; Ioan-Facsinay, A.; van Oosterhout, M.; Jiskoot, W.; Huizinga, T.W.J.; Toes, R.E.M.; Scherer, H.U. Fc gamma receptor binding profile of anti-citrullinated protein antibodies in immune complexes suggests a role for FcγRI in the pathogenesis of synovial inflammation. Clin. Exp. Rheumatol. 2018, 36, 284–293.
  67. Kelton, J.G.; Sheridan, D.; Santos, A.; Smith, J.; Steeves, K.; Smith, C.; Brown, C.; Murphy, W.G. Heparin-induced thrombocytopenia: Laboratory studies. Blood 1988, 72, 925–930.
  68. Chong, B.H.; Fawaz, I.; Chesterman, C.N.; Berndt, M.C. Heparin-induced thrombocytopenia: Mechanism of interaction of the heparin-dependent antibody with platelets. Br. J. Haematol. 1989, 73, 235–240.
  69. Greinacher, A.; Selleng, K.; Mayerle, J.; Palankar, R.; Wesche, J.; Reiche, S.; Aebischer, A.; Warkentin, T.E.; Muenchhoff, M.; Hellmuth, J.C.; et al. Anti-platelet factor 4 antibodies causing VITT do not cross-react with SARS-CoV-2 spike protein. Blood 2021, 138, 1269–1277.
  70. Bruneau, C.D.; Edmonds, J.P.; Hughes, G.R.; Aarden, L. Detection and characterization of DNA-anti-DNA complexes in a patient with systemic lupus erythematosus. Clin. Exp. Immunol. 1977, 28, 433–436.
  71. Patiño-Trives, A.M.; Pérez-Sánchez, C.; Pérez-Sánchez, L.; Luque-Tévar, M.; Ábalos-Aguilera, M.C.; Alcaide-Ruggiero, L.; Arias-de la Rosa, I.; Román-Rodríguez, C.; Seguí, P.; Espinosa, M.; et al. Anti-dsDNA Antibodies Increase the Cardiovascular Risk in Systemic Lupus Erythematosus Promoting a Distinctive Immune and Vascular Activation. Arterioscler. Thromb. Vasc. Biol. 2021, 41, 2417–2430.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
This entry is offline, you can click here to edit this entry!
ScholarVision Creations
Feedback